期刊文献+

微量白蛋白尿与脑梗死面积的关系探讨 被引量:7

下载PDF
导出
摘要 目的探讨脑梗死患者微量白蛋白尿水平变化与脑梗死面积之间的关系。方法用比浊法测尿微量白蛋白值,比较大梗死组、中梗死组、腔隙性梗死组及对照组微量白蛋白尿的阳性率及尿微量白蛋白水平。结果微量白蛋白尿阳性率大梗死组62.4%、中梗死组58.9%、腔隙性梗死组54.5%,对照组32.6%。尿微量白蛋白水平大梗死组(22.56±14.28mg/L)、中梗死组(16.82±11.78mg/L)、腔隙性梗死组(11.76±10.28mg/L)、对照组(7.12±10.12mg/L)。3个脑梗死组与对照组比较差异均有统计学意义(P<0.05),大梗死组、中梗死组与腔隙性组比较有统计学意义(P<0.05)。结论脑梗死患者呈现微量白蛋白尿高发率;尿微量白蛋白水平越高,梗死面积越大。可为临床预后的预测因子。
出处 《心脑血管病防治》 2013年第1期48-50,共3页 CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT
  • 相关文献

参考文献11

  • 1Wada M, Nagasawa H, Kurita K, et al. Microalbmrfinuria is a risk factor for cerebral small vessel disease in community-based elderly subjects[J]. J Neurol Sci, 2007,255 ( 1 ) : 27 - 34.
  • 2Ovbiagele B. Microalbuminurial: risk factor and potential therapeutic targetfor stroke[J]? J Neurol Sei,2008,271(1):21- 8.
  • 3各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380. 被引量:33029
  • 4Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment[J]. Stroke, 1993, 24(1):35-41.
  • 5陈仁涉,高芳坤,魏洁.微量白蛋白尿的发生机理、预后及治疗[J].国外医学(临床生物化学与检验学分册),1997,18(4):156-158. 被引量:52
  • 6吴峻,孙明,周宏研.高血压微量蛋白尿形成与血管及肾小球损害的关系[J].湖南医科大学学报,2002,27(6):512-514. 被引量:12
  • 7Feldt-Rasrnussen B. Microalbuminuria, endothelial dysfunction and cardio- vascular risk[J]. DiabetesMetab,2000,26(supp14) :64 - 66.
  • 8Garg JP, Bakris GL. Microalbuminuria: marker of vasculardysfunction, risk factor for cardiovascular disease[J]. VascMed, 2002,7( 1 ) :35 -43.
  • 9Cao JJ, Barzilay JI, Peterson D, et al. The association ofmi-croalbuminuria with clinical cardiovascular disease and subclini-cal atherosclemsis in the elderly: The cardiovascular healthstudy [ J ]. Atherosclemsis, 2006, 187 (2) :372 - 377.
  • 10Lee M, Saver JL, Chang KH, et al. Impact of microalbuminuria on inci-dent stroke: a meta-analysis[ J]. Stroke, 2010,41 ( 11 ) : 2625 - 2631.

二级参考文献8

  • 1Hartland A, Gosling P. Microalbuminuria: yet another cardiovascular risk factor?[J].Ann Clin Biochem, 1999, 36:700-703.
  • 2Alderman MH, Cohen H, Madhavan S. Epidemiology of risk in hypertensive: experience in treated patients[J]. Am J Hypertens, 1998, 11:874-876.
  • 3Bianchi S, Bigazzi R, Campese MV. Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications[J]. Am J Kidney Dis, 1999, 34:976-995.
  • 4Egido J. Vasoactive hormones and renal sclerosis[J]. Kidney Int, 1996, 49:578-582.
  • 5Redon J. Treatment of patients with hypertension and microalbuminuria[J]. Drugs, 1997, 54:857-866.
  • 6Bigazzi R, Bianchi S, Baldari D, et al. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension[J]. J Hypertens, 1998, 16:1325-1333.
  • 7谢秀梅,余国龙,周萍.芦沙坦对轻、中度高血压病患者血小板活化和肾功能的影响[J].湖南医科大学学报,2002,27(2):130-132. 被引量:1
  • 8吴峻,孙明,周宏研.Losartan逆转钙超负荷及对高血压肾的保护作用[J].中国病理生理杂志,2002,18(7):816-818. 被引量:9

共引文献33090

同被引文献73

引证文献7

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部